🇺🇸·Jun 13Industry
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
Publisher
M
Merck (MSD) News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Merck (MSD) News
- Region
- USA
- Scope
- Industry
- Published
- June 13, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on merck.com
Leave the platform to read the original full article on the publisher site.
Source: Merck (MSD) News
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News/5h ago
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
Eli Lilly News/5h ago
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Recordati/7h ago
On behalf of Respighi BidCo S.p.A – Press Release pursuant to Article 36 of the Issuers’ Regulation
Ipsen/8h ago